Health ❯Healthcare

Clinical Trials

Drug Development Drug Efficacy Phase 3 Trials Patient Outcomes Randomized Controlled Trials Research Studies Cancer Research Drug Approval Phase III Trials Efficacy Studies

Viking Therapeutics Shares Plunge After Obesity Pill Data Show High Dropouts, GI Issues

The mid-stage readout compared unfavorably with rival oral programs, dimming Viking’s near-term prospects.

Stories older than 24h

KRAS-Targeted Vaccine Shows Robust Immune Response, Longer-Than-Expected Survival in Pancreatic and Colorectal Cancer Trial

Bio Protocol Jumps to Six-Month High as Trading Volume Soars and Staking Climbs

Kidney Organoids Reveal NFκB‑Linked AAV2 Toxicity, With Bardoxolone Methyl Mitigating Damage

European Commission Approves Ogsiveo as First Therapy for Desmoid Tumors

TIM‑3 Triplet Therapy Shows Promise in Immunotherapy‑Resistant Melanoma Models

Mango Swap for Bread Shows Short-Term Gains in Type 2 Diabetes, Studies Find

FDA Approves First New Fibromyalgia Treatment in 15 Years

FDA Approves Papzimeos as First Therapy for Adult Recurrent Respiratory Papillomatosis

MHRA Licenses Teplizumab to Delay Onset of Type 1 Diabetes

Two-Dose Dalbavancin Regimen Noninferior to Standard Therapy for Complicated Staph Bacteremia

Intratumoral Fc-Optimized CD40 Antibody Achieves Systemic Remissions in Phase 1 Study

TAR-200 Clears Tumors in 82% of High-Risk Bladder Cancer Patients, Advances to FDA Priority Review

FDA Grants De Novo Authorization to ArteraAI Prostate

AI-Informed Pipeline Accelerates Bi-Specific CAR-T Design and Clears Tumors in Mice

Danish Real-World Study Finds PSMA PET/CT Before Salvage Radiotherapy Boosts Prostate Cancer Survival

FDA Approves Brensocatib as First Treatment for Non-Cystic Fibrosis Bronchiectasis

FDA Approves Vizz Eye Drops to Treat Presbyopia

mRNA Neoantigen Vaccine Amplifies Anti-PD-1 Immunity and Suppresses Gastric Cancer Spread in Mice

Two-Dose Dalbavancin Regimen Matches Standard IV Therapy in Complicated Staph Bacteremia